VX-950-C211 - A Dosing Regimen Study (Twice Daily Versus Every 8 Hours) of Telaprevir in Treatment-naïve Participants With Genotype 1 Chronic Hepatitis C Virus Infection

NCT01241760 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

744

Enrollment

INDUSTRY

Sponsor class

Conditions

Genotype 1 Chronic Hepatitis C
Treatment Naive

Interventions

DRUG: Ribavirin
DRUG: Telaprevir
DRUG: Pegylated interferon alfa-2a
DRUG: Telaprevir

Sponsor

Janssen Infectious Diseases BVBA

Collaborators

[object Object]